Bone最新文献

{"title":"A real-world analysis of the clinical and healthcare burden associated with osteogenesis imperfecta","authors":"Pranav Abraham,&nbsp;Gandarvaka Miles,&nbsp;Natalia Petruski-Ivleva,&nbsp;Kalyani Hawaldar,&nbsp;Cemre Robinson,&nbsp;Kenneth I. Berger","doi":"10.1016/j.bone.2025.117572","DOIUrl":"10.1016/j.bone.2025.117572","url":null,"abstract":"<div><h3>Introduction</h3><div>The healthcare resource utilization (HCRU) and cost burden of osteogenesis imperfecta (OI) in US clinical practice is currently unclear.</div></div><div><h3>Methods</h3><div>This real-world, retrospective study assessed patients with ≥1 inpatient claim or ≥ 2 outpatient claims with <em>ICD-10</em> codes for OI using Optum's deidentified Clinformatics® Data Mart Database (Oct 1, 2015–Nov 30, 2023). Patients were required to have ≥24 months' continuous healthcare plan enrollment; index date was first claim with OI diagnosis code. Patients with OI were matched 1:5 with non-OI patients on age, sex, index date, and follow-up duration. Comorbidities, fractures, HCRU, and costs per person-year (PPY) were stratified by age (≤19 years, 20–54 years, ≥55 years). Continuous and categorical variables were compared using <em>t-</em>tests and chi-square tests, respectively. Generalized linear and logistic regression models were constructed for HCRU and costs.</div></div><div><h3>Results</h3><div>Overall, 1367 patients with OI (≤19 years, <em>n</em> = 324; 20–54 years, <em>n</em> = 521; ≥55 years, <em>n</em> = 522) were matched with 6835 non-OI controls. HCRU was more frequent in patients with OI versus controls; PPY inpatient admissions were 0.17 versus 0.05 (≤19 years), 0.20 versus 0.11 (20–54 years), and 0.32 versus 0.15 (≥55 years) (<em>p</em> &lt; 0.01). OI patients had higher total healthcare costs than non-OI controls (≤19 years, $26,892 vs $10,134; 20–54 years, $27,673 vs $16,101; ≥55 years, $42,335 vs $25,143 PPY) (<em>p</em> &lt; 0.01), driven by increased outpatient visits (pediatrics) and inpatient admissions (adults).</div></div><div><h3>Conclusion</h3><div>Substantial clinical and economic burden was observed in patients with OI in US clinical practice. These findings may inform evaluation of disease-modifying therapies.</div></div>","PeriodicalId":9301,"journal":{"name":"Bone","volume":"200 ","pages":"Article 117572"},"PeriodicalIF":3.5,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fractal analysis of mandibular bone structure in children with amelogenesis imperfecta","authors":"Tulin Tasdemir ,&nbsp;Melek Tassoker","doi":"10.1016/j.bone.2025.117571","DOIUrl":"10.1016/j.bone.2025.117571","url":null,"abstract":"<div><h3>Objective</h3><div>Amelogenesis imperfecta (AI) is a hereditary disorder that affects the structure and composition of primary and permanent teeth. Genetic mutations of AI, especially in the FAM83H gene, can reduce osteogenic marker expression and impair bone mineralization. This study aims to assess radiomorphometric indices and fractal dimension (FD) in dental panoramic radiographs of children with AI and to identify differences compared to control subjects.</div></div><div><h3>Study design</h3><div>The study involved 12 patients with AI and 12 age- and gender-matched healthy individuals. Mandibular Cortex Index [1]. scores were assessed, and fractal analysis using ImageJ was conducted on selected regions from the condyle, gonial, and interdental areas to calculate FD values. Statistical analyses were performed using the Student <em>t</em>-test for normally distributed variables, the Mann-Whitney <em>U</em> test for non-normally distributed variables, and the chi-square test for categorical variables, with <em>p</em> &lt; 0.05 considered statistically significant.</div></div><div><h3>Results</h3><div>Analysis of FD values revealed significant differences on the right side, where controls exhibited higher FD values than AI patients (<em>p</em> = 0.011 for condyle and gonial regions, <em>p</em> = 0.041 for dentate region). No significant differences were observed on the left side. Regarding MCI, the most common score was C1 in both groups, with no significant difference in distribution (<em>p</em> = 0.667).</div></div><div><h3>Conclusion(s)</h3><div>It was found that the FD of the mandibular bone in AI patients was lower than in healthy individuals and this was more pronounced on the right side. The results suggest that AI may affect not only tooth enamel but also the mandibular bone structure.</div></div>","PeriodicalId":9301,"journal":{"name":"Bone","volume":"199 ","pages":"Article 117571"},"PeriodicalIF":3.5,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cathepsin D and G expression correlates with human fracture healing phases and specific neutrophil N1 and N2 phenotypes","authors":"Fangzhou Lu ,&nbsp;Rald V.M. Groven ,&nbsp;Dennis M. Meesters ,&nbsp;Albert Bitorina ,&nbsp;Martijn Poeze ,&nbsp;Shan Tang ,&nbsp;Martijn van Griensven ,&nbsp;Taco J. Blokhuis ,&nbsp;Ronit Shiri-Sverdlov","doi":"10.1016/j.bone.2025.117574","DOIUrl":"10.1016/j.bone.2025.117574","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;The role and involvement of immune cells in the fracture healing cascade, specifically neutrophils, is not yet fully understood. During tissue regeneration, cathepsin (CTS) D and cathepsin G have been identified as being involved in various cellular processes and associated with neutrophil function. This study aimed to determine the expression of these 2 cathepsins in fracture hematoma. Firstly, these two cathepsins were identified and scrutinized using a bioinformatics approach. Secondly, these two cathepsins were investigated for their expression in the human fracture hematoma (FH) as well as in N1 (pro-inflammatory) and N2 (regenerative) neutrophil phenotypes.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;To review the latest research on CTSD and G gene expressions in fracture healing, bioinformatics analysis was firstly performed. Subsequently, to identify CTSD and G genes, the expression of them was assessed in human FH samples throughout different phases of the fracture healing cascade, and potential correlations with patient characteristics were explored. To confirm that gene expression translated to protein production, their corresponding protein levels in FH were evaluated &lt;em&gt;via&lt;/em&gt; immunofluorescence. Finally, human neutrophils were harvested and polarized into N0, N1, or N2 phenotypes, after which their expression of CTSD and CTSG was analyzed.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Bioinformatics analysis revealed distinct expression patterns of CTSD and CTSG in the fracture healing cascade in one earlier rodent study. In human, 58 FHs (0–19 days post-trauma) were harvested. The expression of CTSD significantly increased over fracture healing time, while the expression of CTSG remained constant throughout the early phases of fracture healing. Both proteins were found to be expressed throughout the FH. In neutrophils from five human donors, the expression of CTSD was higher in N2 neutrophils compared to N1, while CTSG was expressed more in N1 compared to N2 neutrophils.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;This study was the first to investigate the association of CTSD and CTSG in the fracture healing cascade. It was shown that the expression of CTSD enzyme was associated with early fracture healing phases, as well as with specific neutrophil phenotypes (N1 or N2). Furthermore, these expression dynamics of CTSD and CTSG support the increasing N2/N1 phenotype ratio over time during fracture healing in humans, reflecting a shift from inflammation to regeneration.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;The translational potential of this article&lt;/h3&gt;&lt;div&gt;This study determined to investigate the cathepsin D and G expression in human fracture healing after reviewing the latest research progress. Along with characterizing the dynamics of these cathepsins in fracture hematoma, we demonstrate their association with two distinct neutrophil phenotypes, N1 and N2. These findings enhance the understanding of cathepsins and the roles of N1 and","PeriodicalId":9301,"journal":{"name":"Bone","volume":"199 ","pages":"Article 117574"},"PeriodicalIF":3.5,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144518328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the letter to the editor: “Global, regional, and national burden and trends analysis of malignant neoplasm of bone and articular cartilage from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021”","authors":"Jianqiang Lai","doi":"10.1016/j.bone.2025.117569","DOIUrl":"10.1016/j.bone.2025.117569","url":null,"abstract":"","PeriodicalId":9301,"journal":{"name":"Bone","volume":"199 ","pages":"Article 117569"},"PeriodicalIF":3.5,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relation of lateral lumbar spine DXA to age-related bone loss, aortic calcification, scoliosis and vertebral degeneration: Analysis of over 10,000 patients","authors":"Nina E. Hänninen ,&nbsp;Antti Voss ,&nbsp;Suvi Hartikainen ,&nbsp;Tomi Nissinen ,&nbsp;Pentti Rautio ,&nbsp;Reijo Sund ,&nbsp;Sami P. Väänänen","doi":"10.1016/j.bone.2025.117564","DOIUrl":"10.1016/j.bone.2025.117564","url":null,"abstract":"<div><div>Dual-energy X-ray absorptiometry (DXA) is a valuable tool for measuring bone mineral density (BMD). Conventional skeletal projection images for BMD assessment include the hip and the posterior-anterior (PA) lumbar spine DXA scans. However, the PA view suffers from the pileup of anatomical structures which are not present in the lateral view. This study aimed to evaluate the significance of lateral projection in measuring BMD.</div><div>We acquired a dataset covering over 10,000 patients with the lateral projection included in the routine clinical DXA examination together with PA lumbar spine and femur projections. Age-related BMD decrease was more pronounced in the lateral lumbar spine and femur than in the PA lumbar spine. To elaborate on this difference, we estimated aortic calcification score from lateral spine DXA images and detected degeneration and scoliosis from PA lumbar spine images using neural networks. Multivariate linear regression analysis suggested that aortic calcification increased BMD in PA spine, but in lateral spine and femur, the expected decline in BMD was observed. The spinal degeneration was related to higher BMD in all sites, with the largest effect on PA spine BMD. Scoliosis increased BMD on lateral spine but was associated with decreased BMD in PA spine and at femur.</div><div>Lateral lumbar spine DXA helped to reveal sources for the artificially elevated BMD and provided better insight into age-related decrease in vertebral bone mineral density than the PA scan. Lateral projection should therefore be considered more in clinical practice, as it enhances the reliability of lumbar spine BMD measurement.</div></div>","PeriodicalId":9301,"journal":{"name":"Bone","volume":"199 ","pages":"Article 117564"},"PeriodicalIF":3.5,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144322685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers and therapeutic targets in giant cell tumor of bone: A comprehensive review","authors":"Veronika Knechtova ,&nbsp;Michal Mahdal ,&nbsp;Iva Staniczkova Zambo ,&nbsp;Jan Skoda ,&nbsp;Jakub Neradil","doi":"10.1016/j.bone.2025.117566","DOIUrl":"10.1016/j.bone.2025.117566","url":null,"abstract":"<div><div>Giant cell tumor of bone (GCTB) is an intermediate locally aggressive osteolytic tumor with low metastatic potential and a high recurrence rate. It comprises two main types of cells—neoplastic mononuclear stromal cells and osteoclast-like giant cells—which are responsible for the resorption of bone. In addition to surgery, which is the primary treatment of choice, adjuvant therapy is used to lower the risk of recurrence. However, denosumab, the standard adjuvant treatment currently used, only targets osteoclast-like giant cells and does not affect neoplastic stromal cells. Since some GCTBs are inoperable, or even after surgery, there can be residual tumor cells at the site of the tumor, novel therapies, especially those that target neoplastic stromal cells, are needed. Both cell types in GCTB show altered expression of various specific genes and molecules, and these deregulated molecular profiles could serve as biomarkers and targets for targeted therapy. Herein, we summarize the potential biomarkers for both cell types in GCTB and therapeutic agents targeting these molecules with the hope of finding a therapy with improved outcomes and a lower risk of recurrence.</div></div>","PeriodicalId":9301,"journal":{"name":"Bone","volume":"199 ","pages":"Article 117566"},"PeriodicalIF":3.5,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144313985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potent suppression of bone remodeling by denosumab does not blunt the anabolic response to romosozumab in mice","authors":"Cecile Bustamante-Gomez ,&nbsp;Qiang Fu ,&nbsp;Joseph J. Goellner ,&nbsp;Jeff D. Thostenson ,&nbsp;Humberto Reyes-Pardo ,&nbsp;Charles A. O'Brien","doi":"10.1016/j.bone.2025.117567","DOIUrl":"10.1016/j.bone.2025.117567","url":null,"abstract":"<div><div>Histological analyses suggest that sclerostin inhibition increases bone mass primarily by stimulating modeling-based bone formation. However, clinical studies show that anti-resorptive therapies, which inhibit bone remodeling, blunt the anabolic effect of the anti-sclerostin antibody romosozumab. Moreover, suppressing remodeling inhibits bone formation in <em>Sost</em>-deficient mice. These latter studies suggest that bone remodeling is required for the full anabolic effect of sclerostin suppression. To address this, we suppressed bone remodeling in mice using the anti-RANKL antibody denosumab and then administered romosozumab, along with continued denosumab. Controls received either vehicle, denosumab alone, or romosozumab alone. The romosozumab-induced increase in bone was not blunted by denosumab. Similarly, the romosozumab-induced increases in osteoblast number and bone formation were not altered by denosumab. The anabolic effect of romosozumab was also not altered in a mouse model of rebound resorption caused by denosumab discontinuation. Nonetheless, denosumab reduced bone formation in Sost-deficient mice. These results demonstrate a striking difference in the dependence on bone remodeling for the anabolic effects of sclerostin suppression versus genetic inactivation of Sost and suggest distinct mechanisms drive osteoblast production in the two conditions. In addition, they suggest that the blunted response to romosozumab in clinical studies is not due to suppressed remodeling.</div></div>","PeriodicalId":9301,"journal":{"name":"Bone","volume":"199 ","pages":"Article 117567"},"PeriodicalIF":3.5,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144313986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor: “An analysis of 12 major fracture subtypes in adolescents and young adults: Global trends and population projections from GBD 2021”","authors":"Qiyuan Cheng","doi":"10.1016/j.bone.2025.117568","DOIUrl":"10.1016/j.bone.2025.117568","url":null,"abstract":"","PeriodicalId":9301,"journal":{"name":"Bone","volume":"199 ","pages":"Article 117568"},"PeriodicalIF":3.5,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144322684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new BMP type 1 receptor kinase inhibitor for safe and efficient oral treatment to prevent genetically induced heterotopic ossification in mice","authors":"Jingwen Yang ,&nbsp;Haichun Pan ,&nbsp;Katsuhiko Sekimata ,&nbsp;Charles Hwang ,&nbsp;Anshul Kulkarni ,&nbsp;Hannah Thomas ,&nbsp;Jade Lindenau ,&nbsp;Tyler Duford ,&nbsp;Hiroki Ueharu ,&nbsp;Akiko Tanaka ,&nbsp;Naoki Sakai ,&nbsp;Mikako Shirouzu ,&nbsp;Yoshinobu Hashizume ,&nbsp;Benjamin Levi ,&nbsp;Hiroo Koyama ,&nbsp;Yuji Mishina","doi":"10.1016/j.bone.2025.117565","DOIUrl":"10.1016/j.bone.2025.117565","url":null,"abstract":"<div><div>Fibrodysplasia ossificans progressiva (FOP) is a rare genetic heterotopic ossification (HO) disorder that currently lacks a practical and definitive preventative approach. FOP is driven by gain-of-function variants in ACVR1, increasing dysregulated BMP signaling pathway, thus resulting in progressive and permanent replacement of skeletal muscle and connective tissues with heterotopic bone, ultimately leading to severe debilitation and premature death. Here, we describe the discovery of RK783, a small-molecule that inhibit BMP type 1 receptor kinase developed for treating FOP. This compound, the result of a rigorous process that involved screening approximately 140,000 compounds in silico with ligand-based structure followed by inhibitory activity and pharmacokinetics studies, offers a promising new direction in treating FOP. RK783 preferentially suppressed both basal and stimulated BMP-Smad1/5/9 signaling in vitro without affecting the signaling of Smad2/3. In vivo, the efficacy of RK783 was demonstrated using two FOP mice models, a conditional knock-in <em>ACVR1-R206H</em> and a transgenic <em>ACVR1-Q207D</em> mouse model, where oral dosing suppressed infiltration of immune cells and differentiation of fibroblast-adipose progenitor (FAP) cells, thus preventing ectopic cartilage and HO formation in muscles. Optimized dosing revealed that high and frequent treatment within the first couple of days after HO induction is critical to successfully suppress HO by RK738. These data suggest that RK783 can be used as an acute medication to prevent HO in FOP.</div></div>","PeriodicalId":9301,"journal":{"name":"Bone","volume":"199 ","pages":"Article 117565"},"PeriodicalIF":3.5,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of Zoledronate administration routes on the reproducibility of BRONJ in rodent models: A systematic review","authors":"Meircurius Dwi Condro Surboyo ,&nbsp;Prasiddha Mahardhika El Fadhlallah ,&nbsp;Yurie Sato-Yamada ,&nbsp;Kridtapat Sirisereephap ,&nbsp;Meiwen Fang ,&nbsp;Takeyasu Maeda ,&nbsp;Kei Tomihara ,&nbsp;Koichi Tabeta ,&nbsp;Nagako Yoshiba ,&nbsp;Andrea L. Rosenkranz ,&nbsp;Tomoki Maekawa","doi":"10.1016/j.bone.2025.117563","DOIUrl":"10.1016/j.bone.2025.117563","url":null,"abstract":"<div><h3>Objective</h3><div>Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a debilitating condition characterized by alveolar bone destruction associated with bisphosphonate medications, such as zoledronate. Zoledronate use is associated with an increased incidence of BRONJ. In rodent models, accurate replication of BRONJ stages depends on the route of zoledronate administration. This systematic review evaluates the reproducibility of BRONJ characteristics in rodent models by analyzing the effects of different zoledronate injection routes on clinical, histopathological, and radiological outcomes.</div></div><div><h3>Methods</h3><div>A systematic literature search was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines using keywords related to BRONJ and zoledronate. The following data were collected from the selected studies: characteristics of mice and rats; zoledronate dose, duration, and route of administration. The BRONJ stage was determined in these studies based on clinical, histopathological, and radiological features of alveolar bone necrosis.</div></div><div><h3>Results</h3><div>Zoledronate treatment notably affected the reproducibility of BRONJ characteristics. Mice and rats exhibited distinct characteristics in producing BRONJ, depending on the route of zoledronate injection. Subcutaneous, intraperitoneal (IP), and intravenous (IV) injections in rats consistently produced exposed alveolar bone, the main criterion for clinical BRONJ. IP and IV zoledronate injection in mice produced a clinical BRONJ model. Neither mice nor rats exhibited differences in BRONJ characteristics according to sex.</div></div><div><h3>Conclusions</h3><div>Rodent models of BRONJ mimic the staging and characteristics of BRONJ observed in humans. Rat BRONJ models were more consistently reproducible when the zoledronate administration route was tailored to achieve specific research objectives.</div></div>","PeriodicalId":9301,"journal":{"name":"Bone","volume":"199 ","pages":"Article 117563"},"PeriodicalIF":3.5,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}